First Patient Dosed in Ph 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy
“Relapsed/refractory T-ALL/LBL remains one of the most difficult-to-treat blood cancers, with 40% of adults relapsing after first-line therapy and facing very limited options,” said Jan Davidson-Moncada, MD, PhD, Imviva Biotech Chief Medical Officer. “The successful dosing of our first U.S. patient represents a meaningful milestone in bringing an innovative off-the-shelf CAR-T therapy to this underserved population. We are well-positioned to advance to Phase 2 in the near future and establish CTD402 as a therapeutic option for patients who urgently need better treatments.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo